Table 4.
Univariate and multivariate logistic analyses for the in-hospital AHF risk in NSTEMI patients.
| Parameters for AHF (NSTEMI) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age (years) | 1.013 | 0.991–1.036 | <0.001 | 1.003 | 0.980–1.027 | 0.795 |
| Sex, male, n (%) | 1.398 | 0.751–2.604 | 0.290 | |||
| Smoking, n (%) | 0.720 | 0.389–1.334 | 0.296 | |||
| Hypertension, n (%) | 1.418 | 0.747–2.730 | 0.295 | |||
| Diabetes, n (%) | 1.463 | 0.785–2.726 | 0.231 | |||
| LDL-C (mmol/L) >3.4 | 1.190 | 0.563–2.513 | 0.649 | |||
| HDL-C (mmol/L) <1.04 | 1.526 | 0.820–2.840 | 0.182 | |||
| BNP (pg/mL) >400 | 1.690 | 0.900–3.172 | 0.102 | |||
| CPK (U/L) >200 | 1.439 | 0.797–2.597 | 0.227 | |||
| CK-MB (U/L) >20 | 1.681 | 0.886–3.190 | 0.112 | |||
| HBDH (U/L) >182 | 2.603 | 1.316–5.149 | 0.006 | 2.240 | 1.106–4.534 | 0.025 |
| NLR >median | 2.155 | 1.167–3.978 | 0.014 | 2.336 | 1.236–4.416 | 0.009 |
| β-block, n (%) | 1.183 | 0.653–2.144 | 0.579 | |||
| ACEI/ARB, n (%) | 0.814 | 0.422–1.570 | 0.539 | |||
| ARNI, n (%) | 0.399 | 0.181–0.879 | 0.156 | |||
| SGLT2i, n (%) | 0.282 | 0.109–0.731 | 0.009 | 0.326 | 0.118–0.900 | 0.031 |
| MRA, n (%) | 0.597 | 0.337–1.041 | 0.005 | 0.872 | 0.342–2.143 | 0.007 |
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BNP, brain natriuretic peptide; CPK, creatine phosphokinase; CK-MB, creatine kinase-MB; HBDH, hydroxybutyrate dehydrogenase; ARNI, angiotensin receptor-neprilysin inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; MRA, mineralocorticoid receptor antagonist.